South Korea-based medical AI developer Lunit has partnered with AstraZeneca to integrate Lunit's Scope Genotype Predictor into pathology workflows in screening for actionable mutations in non-small cell lung cancer (NSCLC) research.
Scope Genotype Predictor is designed to analyze hematoxylin and eosin (H&E) slide images to predict the likelihood of a tumor harboring NSCLC driver mutations, such as epidermal growth factor receptor (EGFR) mutations, using deep-learning algorithms, according to Lunit.
Together, AstraZeneca and Lunit hope to further develop the screening tool and, following validation, explore its deployment in real-world settings to assess risk of lung driver mutations, and inform further molecular testing, Lunit said.
As part of this collaboration, Lunit and AstraZeneca will also explore additional future molecular biomarker predictions based on H&E slide analysis, enabling their future development and extensive validation, according to Lunit.
